The stock reached its price target, so now what do the charts say?
Here's how to play the stock.
I've got an option play in Biohaven Pharmaceuticals -- after an earlier trade prior to the Pfizer buyout.
Let's see how things develop.
Seasoned traders who understand risk could nibble on the long side of ALDX.
The shares have taken off and we have new price targets.
One has to think that next year's earnings may get a little wonky.
The charts of the big drugmaker present a mixed picture ahead of its third-quarter results.
The shares are now trading above the rising 50-day moving average line and above the rising 200-day moving average line.